<?xml version='1.0' encoding='utf-8'?>
<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
  <article article-type="research-article" xml:lang="en" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Mayo Clin Proc Innov Qual Outcomes</journal-id>
        <journal-id journal-id-type="iso-abbrev">Mayo Clin Proc Innov Qual Outcomes</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3533</journal-id>
        <journal-id journal-id-type="pmc-domain">mayocpiqs</journal-id>
        <journal-title-group>
          <journal-title>Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2542-4548</issn>
        <publisher>
          <publisher-name>Elsevier</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8526905</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8526905.1</article-id>
        <article-id pub-id-type="pmcaid">8526905</article-id>
        <article-id pub-id-type="pmcaiid">8526905</article-id>
        <article-id pub-id-type="pmid">34703985</article-id>
        <article-id pub-id-type="doi">10.1016/j.mayocpiqo.2021.05.003</article-id>
        <article-id pub-id-type="pii">S2542-4548(21)00070-9</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Original Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>
            <italic toggle="yes">BRAF</italic> V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" id="au1">
            <name name-style="western">
              <surname>Slostad</surname>
              <given-names initials="JA">Jessica A.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff1" ref-type="aff">a</xref>
          </contrib>
          <contrib contrib-type="author" id="au2">
            <name name-style="western">
              <surname>Liu</surname>
              <given-names initials="MC">Minetta C.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff2" ref-type="aff">b</xref>
            <xref rid="aff3" ref-type="aff">c</xref>
          </contrib>
          <contrib contrib-type="author" id="au3">
            <name name-style="western">
              <surname>Allred</surname>
              <given-names initials="JB">Jacob B.</given-names>
            </name>
            <degrees>MS</degrees>
            <xref rid="aff4" ref-type="aff">d</xref>
          </contrib>
          <contrib contrib-type="author" id="au4">
            <name name-style="western">
              <surname>Erickson</surname>
              <given-names initials="LA">Lori A.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff2" ref-type="aff">b</xref>
          </contrib>
          <contrib contrib-type="author" id="au5">
            <name name-style="western">
              <surname>Rumilla</surname>
              <given-names initials="KM">Kandelaria M.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff5" ref-type="aff">e</xref>
            <xref rid="aff6" ref-type="aff">f</xref>
          </contrib>
          <contrib contrib-type="author" id="au6">
            <name name-style="western">
              <surname>Block</surname>
              <given-names initials="MS">Matthew S.</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff2" ref-type="aff">b</xref>
          </contrib>
          <contrib contrib-type="author" id="au7">
            <name name-style="western">
              <surname>Keppen</surname>
              <given-names initials="M">Michael</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff6" ref-type="aff">f</xref>
          </contrib>
          <contrib contrib-type="author" id="au8">
            <name name-style="western">
              <surname>King</surname>
              <given-names initials="D">David</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff7" ref-type="aff">g</xref>
          </contrib>
          <contrib contrib-type="author" id="au9">
            <name name-style="western">
              <surname>Markovic</surname>
              <given-names initials="SN">Svetomir N.</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff2" ref-type="aff">b</xref>
          </contrib>
          <contrib contrib-type="author" id="au10">
            <name name-style="western">
              <surname>McWilliams</surname>
              <given-names initials="RR">Robert R.</given-names>
            </name>
            <degrees>MD</degrees>
            <email>mcwilliams.robert@mayo.edu</email>
            <ext-link ext-link-type="uri" ns0:href="https://twitter.com/@JessSlostadMD">@JessSlostadMD</ext-link>
            <xref rid="aff2" ref-type="aff">b</xref>
            <xref rid="cor1" ref-type="corresp">∗</xref>
          </contrib>
          <aff id="aff1">
            <label>a</label>Division of Hematology-Oncology, Rush University Medical Center, Chicago, IL</aff>
          <aff id="aff2">
            <label>b</label>Division of Medical Oncology, Mayo Clinic, Rochester, MN</aff>
          <aff id="aff3">
            <label>c</label>Department of Laboratory Medicine and Pathology, Clinical Genomics, Mayo Clinic, Rochester, MN</aff>
          <aff id="aff4">
            <label>d</label>Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN</aff>
          <aff id="aff5">
            <label>e</label>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN</aff>
          <aff id="aff6">
            <label>f</label>Sanford USD Medical Center-Sioux Falls, Sioux Falls, SD</aff>
          <aff id="aff7">
            <label>g</label>Unity Hospital, Fridley, MN</aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor1">
            <label>∗</label>
            <bold>Correspondence:</bold> Address to Robert R. McWilliams, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905. <email>mcwilliams.robert@mayo.edu</email>
            <ext-link ext-link-type="uri" ns0:href="https://twitter.com/@JessSlostadMD">@JessSlostadMD</ext-link>
          </corresp>
        </author-notes>
        <pub-date pub-type="collection">
          <month>12</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>13</day>
          <month>10</month>
          <year>2021</year>
        </pub-date>
        <volume>5</volume>
        <issue>6</issue>
        <issue-id pub-id-type="pmc-issue-id">391183</issue-id>
        <fpage>1012</fpage>
        <lpage>1020</lpage>
        <self-uri content-type="pmc-pdf" ns0:href="main.pdf" />
        <abstract id="abs0010">
          <sec>
            <title>Objective</title>
            <p>To evaluate the prognostic significance of detectable circulating cell-free DNA (cfDNA) <italic toggle="yes">BRAF</italic> V600E/K mutations in patients with advanced melanoma enrolled in a clinical trial without <italic toggle="yes">BRAF</italic>-targeted therapy.</p>
          </sec>
          <sec>
            <title>Patients and Methods</title>
            <p>
              <italic toggle="yes">BRAF</italic> V600E/K mutation status was determined on archived tissue and pretreatment stored plasma from 149 patients with unresectable stage IV melanoma who were enrolled between May 5, 2010 and May 2, 2014 in the North Central Cancer Treatment Group/Alliance N0879 randomized phase 2 clinical trial. Results were reported as presence or absence of cfDNA <italic toggle="yes">BRAF</italic> V600E/K detection of assay vs tissue. Progression-free survival (PFS) and overall survival (OS) were assessed for patients with and without detectable <italic toggle="yes">BRAF</italic> mutation.</p>
          </sec>
          <sec>
            <title>Results</title>
            <p>In total, 63 of 149 (42.3%) patients had <italic toggle="yes">BRAF</italic> V600E/K results for tissue and blood, and 20 of 63 (31.7%) patients had tissue-diagnosed mutant <italic toggle="yes">BRAF</italic>. Of these, 11 of 20 (55.0%) patients had detectable plasma cfDNA <italic toggle="yes">BRAF</italic>. Among patients with tissue-mutant <italic toggle="yes">BRAF</italic> V600E/K, PFS and OS were shorter for those with corresponding cfDNA mutations (PFS, 5.8 vs 12.0 months; <italic toggle="yes">P</italic>=.051; OS, 9.2 vs 27.1 months; <italic toggle="yes">P</italic>=.054). Our assay demonstrated sensitivity of 55% (95% CI, 0.322 to 0.768), specificity of 97.7% (95% CI, 0.932 to 1.000), positive predictive value of 91.7% (95% CI, 0.760 to 1.000), and negative predictive value of 82.4% (95% CI, 0.719 to 0.928).</p>
          </sec>
          <sec>
            <title>Conclusion</title>
            <p>In advanced melanoma, detectable cfDNA <italic toggle="yes">BRAF</italic> V600E/K mutation is present in about half the patients with stage IV with <italic toggle="yes">BRAF</italic>-mutant melanoma tumor tissue and appears to confer a poorer prognosis when detectable. Given the poorer prognosis, cfDNA can be used to risk-stratify patients with metastatic melanoma in practice or clinical trials.<bold>Trial Registration:</bold> clinicaltrials.gov Identifier: <ext-link ext-link-type="uri" ns0:href="http://NCT00976573" id="interref0010">NCT00976573</ext-link>
            </p>
          </sec>
        </abstract>
        <kwd-group id="kwrds0010">
          <title>Abbreviations and Acronyms</title>
          <kwd>cfDNA, cell-free DNA</kwd>
          <kwd>ddPCR, digital droplet polymerase chain reaction</kwd>
          <kwd>FFPE, formalin-fixed paraffin-embedded</kwd>
          <kwd>HR, hazard ratio</kwd>
          <kwd>LDH, lactate dehydrogenase</kwd>
          <kwd>MAPK, mitogen-activated protein kinase</kwd>
          <kwd>NA, not available</kwd>
          <kwd>NCCTG, North Central Cancer Treatment Group</kwd>
          <kwd>NPV, negative predictive value</kwd>
          <kwd>OS, overall survival</kwd>
          <kwd>PFS, progression-free survival</kwd>
          <kwd>PPV, positive predictive value</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-license-ref</meta-name>
            <meta-value>CC BY-NC-ND</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <p id="p0010">The <italic toggle="yes">BRAF</italic> (B-Raf proto-oncogene, serine/threonine kinase) V600 mutations are found in 40% to 60% of advanced melanomas.<xref rid="bib1" ref-type="bibr">
          <sup>1</sup>
        </xref> The <italic toggle="yes">BRAF</italic> V600 mutations have a role in the RAF-MEK-ERK signal transduction pathway and are considered a therapeutic and diagnostic target in melanoma.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref> The current standard of care for detecting tumor mutations involves testing archival formalin-fixed paraffin-embedded (FFPE) tumor tissue. However, tissue may not be obtained or amendable to biopsy, mutation status may change over time, and secondary primary sites and tumor heterogeneity may be present.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> Therefore, noninvasive, highly specific, and rapid testing would benefit patients with advanced melanoma.</p>
      <p id="p0015">Cell-free DNA (cfDNA) is thought to be released from cells undergoing apoptosis or necrosis<xref rid="bib8" ref-type="bibr">
          <sup>8</sup>
        </xref> and may serve as a reliable means to detect tumor-specific mutations, such as <italic toggle="yes">BRAF</italic> V600E, in the blood.<xref rid="bib9" ref-type="bibr">
          <sup>9</sup>
        </xref> Tumor-specific cfDNA is present in low quantities in the blood (&lt;1% of total cfDNA),<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref> posing challenges for achieving the analytical sensitivity and specificity required of a clinical assay. The potential clinical impacts of blood-based cfDNA testing in cancer include quicker turnaround time, more easily obtained and less invasive testing compared with tissue, serial measurements, earlier diagnosis and intervention through screening, earlier detection of cancer recurrence or treatment resistance, and monitoring of response to treatment.<xref rid="bib6" ref-type="bibr">
          <sup>6</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib13" ref-type="bibr">
          <sup>13</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib14" ref-type="bibr">
          <sup>14</sup>
        </xref>
      </p>
      <p id="p0020">There are several methods for assessing mutation status in cfDNA. One validated technique for the detection of <italic toggle="yes">BRAF</italic> V600E or K mutations is digital droplet polymerase chain reaction (ddPCR).<xref rid="bib15" ref-type="bibr">
          <sup>15</sup>
        </xref> Prior studies have reported variable sensitivity (38%-79%) and specificity (85%-100%) of detecting cfDNA for <italic toggle="yes">BRAF</italic> V600.<xref rid="bib1" ref-type="bibr">
          <sup>1</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib10" ref-type="bibr">
          <sup>10</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib16" ref-type="bibr">
          <sup>16</sup>
        </xref> Limitations to these studies include lack of clinical trial populations and the concurrent use of <italic toggle="yes">BRAF</italic>-targeted therapy that could potentially confound outcome results.<xref rid="bib1" ref-type="bibr">
          <sup>1</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib10" ref-type="bibr">
          <sup>10</sup>
        </xref>
      </p>
      <p id="p0025">Five-year survival has improved from the prior <italic toggle="yes">BRAF</italic> era of less than 10% to now 40% to 50% with targeted agents and immunotherapy.<xref rid="bib16" ref-type="bibr">
          <sup>16</sup>
        </xref> Median overall survival (OS) with <italic toggle="yes">MEK/BRAF</italic> inhibition is 22 to 25 months, with 3- to 5-year survival of 40%.<xref rid="bib16" ref-type="bibr">
          <sup>16</sup>
        </xref> However, in patients with poor prognostic features, such as high tumor burden, 3-year OS is still less than 10%.<xref rid="bib16" ref-type="bibr">
          <sup>16</sup>
        </xref>
      </p>
      <p id="p0030">Several studies have assessed the prognostic implications of cfDNA in advanced melanoma.<xref rid="bib2" ref-type="bibr">
          <sup>2</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> In a study by Sanmamed et al,<xref rid="bib2" ref-type="bibr">
          <sup>2</sup>
        </xref> the higher number of copies of cfDNA <italic toggle="yes">BRAF</italic> V600E detected correlated to higher tumor burden and worse OS based on a quantitative cfDNA assay. In a study by Shinozaki et al,<xref rid="bib18" ref-type="bibr">
          <sup>18</sup>
        </xref> which included a cohort of patients treated with chemotherapy, interleukin 2, and interferon alfa-2b, there was a significant difference in OS between patients with and without cfDNA <italic toggle="yes">BRAF</italic> (V600E) detected (13 vs 30.6 months, respectively). However, <italic toggle="yes">BRAF</italic> status in the tumor was unknown.<xref rid="bib18" ref-type="bibr">
          <sup>18</sup>
        </xref> An analysis by Santiago-Walker et al<xref rid="bib17" ref-type="bibr">
          <sup>17</sup>
        </xref> assessed OS and progression-free survival (PFS) of patients with and without cfDNA <italic toggle="yes">BRAF</italic> V600E/K mutations using 4 studies with the <italic toggle="yes">BRAF</italic> inhibitor dabrafenib or the <italic toggle="yes">MEK</italic> inhibitor trametinib. All 4 studies showed superior OS and PFS with absent or low levels of cfDNA.<xref rid="bib17" ref-type="bibr">
          <sup>17</sup>
        </xref> However, a phase 2 study of <italic toggle="yes">MEK</italic>1/2 inhibition (AZD6244) showed no significant difference in PFS in patients with or without cfDNA <italic toggle="yes">BRAF</italic> V600E/K/D mutations who tested positive for <italic toggle="yes">BRAF</italic> mutations in tissue (hazard ratio [HR], 1.08; <italic toggle="yes">P</italic>=.83).<xref rid="bib17" ref-type="bibr">
          <sup>17</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib19" ref-type="bibr">
          <sup>19</sup>
        </xref>
      </p>
      <p id="p0035">Given the variation of prior melanoma cfDNA <italic toggle="yes">BRAF</italic> V600 studies, we aimed to evaluate the prognostic significance of detectable cfDNA <italic toggle="yes">BRAF</italic> V600E/K mutations in a clinical trial population with advanced melanoma in the absence of <italic toggle="yes">BRAF</italic>-targeted therapy.</p>
      <sec id="sec1">
        <title>Methods</title>
        <sec id="sec1.1">
          <title>Study Design</title>
          <p id="p0040">North Central Cancer Treatment Group (NCCTG) N0879 was a randomized phase 2 trial of patients with stage IV melanoma that assessed the chemotherapy regimen of carboplatin, paclitaxel, and bevacizumab with or without everolimus<xref rid="bib9" ref-type="bibr">
              <sup>9</sup>
            </xref> (NCCTG is now part of the Alliance for Clinical Trials in Oncology). Each participant signed an institutional review board–approved protocol-specific informed consent document before tissue and blood sampling.</p>
          <p id="p0045">Stored frozen plasma samples were drawn at study enrollment in the trial before beginning therapy and were stored at −80°C until the time of assay. Archived tissue was extracted for DNA analysis for somatic <italic toggle="yes">BRAF</italic> V600 mutations on a standard clinical platform, which was used as the gold standard for comparison. Baseline blood samples were obtained for cfDNA and analyzed for <italic toggle="yes">BRAF</italic> mutations in a blinded fashion. Clinical outcomes were available prospectively on the clinical trial.</p>
        </sec>
        <sec id="sec1.2">
          <title>Study Population</title>
          <p id="p0050">The study population included 149 patients enrolled between May 5, 2010 and May 2, 2014 from NCCTG (Alliance) N0879 phase 2 clinical trial with unresectable stage IV melanoma.<xref rid="bib9" ref-type="bibr">
              <sup>9</sup>
            </xref> Eligibility criteria included histologic proof of stage IV melanoma and 1 or fewer prior chemotherapy regimen. Exclusion criteria included prior treatment with taxane-based chemotherapy or anti–vascular endothelial growth factor agents, brain metastases before study enrollment, or other significant medical comorbid conditions or malignancies.</p>
        </sec>
        <sec id="sec1.3">
          <title>Tissue Processing and Analysis</title>
          <p id="p0055">Tumor tissue was procured from metastatic or primary biopsy or surgical archived diagnostic FFPE samples when available. The histologic diagnosis of melanoma was confirmed by an expert pathologist (L.A.E.). DNA extracted from FFPE tumor tissue samples and the samples were analyzed using clinical 50-gene hotspot PCR-based MiSeq (Illumina, San Diego, CA) next-generation panel in Mayo Medical Laboratories (<ext-link ext-link-type="uri" ns0:href="https://www.mayomedicallaboratories.com" id="intref0010">https://www.mayomedicallaboratories.com</ext-link>). The <italic toggle="yes">BRAF</italic> exons 11 and 15 and codons 594, 596, and 600 were detected. Hematoxylin and eosin slides were reviewed by 2 pathologists for diagnosis and adequacy to determine appropriate areas for testing before extraction by the QIAamp (Qiagen, Hilden, Germany) DSP DNA FFPE extraction method.</p>
        </sec>
        <sec id="sec1.4">
          <title>Blood Specimen Collection, Processing, and Analysis</title>
          <p id="p0060">Whole blood (10 mL) was collected in EDTA blood collection tubes and shipped at ambient temperature to the Mayo Clinic the day they were drawn. Blood samples were processed by centrifugation to produce aliquots of plasma for cfDNA extraction using the Qiagen QIAamp Circulating Nucleic Acid Kit per manufacturer’s guidelines. Blood collected in EDTA was single spun and stored in 1-mL aliquots at −80°C. The cfDNA was isolated from 3×1-mL plasma aliquots thawed once specifically for use in this analysis. Although double-spun platelet-poor plasma is ideal for next-generation sequencing–based multiplexed ctDNA analyses, single-spun plasma and serum are considered adequate for ddPCR-based analyses of single alterations due to the high sensitivity.<xref rid="bib20" ref-type="bibr">
              <sup>20</sup>
            </xref>
          </p>
          <p id="p0065">The presence of <italic toggle="yes">BRAF</italic> V600E/K was detected through an analytically and clinically validated ddPCR assay optimized for cfDNA analysis by investigators at the Mayo Clinic Laboratory.<xref rid="bib15" ref-type="bibr">
              <sup>15</sup>
            </xref> The RainDrop Digital PCR System (BioRAD) uses Taqman 5′ hydrolysis probes designed to detect wild-type <italic toggle="yes">BRAF</italic> and <italic toggle="yes">BRAF</italic> V600E or K mutations. A standard 18-μL elution volume was used as input for the Raindance ddPCR platform. The cfDNA samples were quantified by Qubit 2.0 (Invitrogen Waltham, MA) before each run as nanograms per 18 μL. Single DNA molecules are encapsulated within droplets of immiscible carrier oil for stabilization in the RainDrop Source instrument (bio-Rad, Hercules, CA), PCR amplified in a thermal cycler with a mixture that contains VIC or FAM conjugated probes, and then transferred to the RainDrop Sense instrument that digitally counts whether amplification of the wild-type or mutant <italic toggle="yes">BRAF</italic> has occurred in each droplet. A positive droplet (<italic toggle="yes">BRAF</italic> mutant) that contains 1 copy of the target that results in increased fluorescence cfDNA was extracted from the stored plasma samples and analyzed for <italic toggle="yes">BRAF</italic> V600E/K mutations using a validated ddPCR-based assay available in the clinical laboratory. <italic toggle="yes">BRAF</italic> V600E/K mutations were identified as “detected” or “not detected.” Tumor fraction was not determined. Individuals performing the laboratory work and analyzing experimental data were blinded to all clinical variables.</p>
        </sec>
        <sec id="sec1.5">
          <title>Statistical Analyses</title>
          <p id="p0070">Time-to-event end points, including OS and PFS, were explored using the Kaplan-Meier method.<xref rid="bib21" ref-type="bibr">
              <sup>21</sup>
            </xref> Follow-up occurred over 43 months. Median times to event were presented along with <italic toggle="yes">P</italic> values from log-rank tests for comparison across groups when appropriate. Because the 2-arm randomized trial was negative for difference between the 2 arms, outcomes were calculated regardless of arm.<xref rid="bib9" ref-type="bibr">
              <sup>9</sup>
            </xref> The relationship between the <italic toggle="yes">BRAF</italic> mutation results obtained from plasma and tissue samples was also evaluated using simple descriptive statistics including sensitivity, specificity, positive predictive value, and negative predictive value. For multivariate analysis, multivariate analysis of the baseline characteristics included study arm, BRAF, age, sex, and LDH level (elevated vs normal). Forward, backward, and stepwise model selection was performed to verify consistency. Data collection and statistical analyses were conducted by the Alliance Statistics and Data Center using SAS (SAS Analytics, Cary, NC), version 9.4M6.</p>
        </sec>
      </sec>
      <sec id="sec2">
        <title>Results</title>
        <sec id="sec2.1">
          <title>Patient Population</title>
          <p id="p0075">Plasma samples were available for 134 of 149 patients enrolled on the N0879 trial. Both tumor tissue and plasma samples were available for 63 patients (<xref rid="fig1" ref-type="fig">Figure 1</xref>).<xref rid="bib9" ref-type="bibr">
              <sup>9</sup>
            </xref> Of the 63 patients with available samples, 20 (31.7%) had tissue-diagnosed mutant <italic toggle="yes">BRAF</italic>, whereas 43 (68.3%) were wild type. Of patients with tissue-diagnosed <italic toggle="yes">BRAF</italic> mutations, 11 (55.0%) had mutant cfDNA <italic toggle="yes">BRAF</italic> detected in the blood. There was 1 patient (2.3%) of the 43 with <italic toggle="yes">BRAF</italic> wild-type tissue with mutant cfDNA <italic toggle="yes">BRAF</italic> in the blood. The sensitivity of the assay was 55% (exact 95% CI, 0.332 to 0.768) and specificity was 97.7% (exact 95% CI, 0.932 to 1.000). The positive predictive value was 91.7% (exact 95% CI, 0.760 to 1.000) and negative predictive value was 82.4% (exact 95% CI, 0.719 to 0.928).<fig id="fig1" position="float" orientation="portrait">
              <label>Figure 1</label>
              <caption>
                <p>Diagram of patient allocation.</p>
              </caption>
              <graphic position="float" orientation="portrait" ns0:href="gr1.jpg" />
            </fig>
          </p>
          <p id="p0080">Patients were similar in both <italic toggle="yes">BRAF</italic>-mutated and <italic toggle="yes">BRAF</italic>–wild-type groups, except primary uveal melanoma comprised 20.9% (9/43 of the <italic toggle="yes">BRAF</italic> wild-type population compared with 0% of the <italic toggle="yes">BRAF</italic>-mutated melanoma population, as expected. Median LDH level (U/L) was slightly higher in patients with undetectable cfDNA <italic toggle="yes">BRAF</italic> V600E/K compared with detectable cfDNA <italic toggle="yes">BRAF</italic> V600E/K (251 vs 210) (<xref rid="tbl1" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl1" orientation="portrait">
              <label>Table 1</label>
              <caption>
                <p>The SAS System</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th rowspan="3" colspan="1" />
                    <th colspan="3" rowspan="1">cfDNA BRAF<hr />
                    </th>
                    <th rowspan="3" colspan="1">
                      <italic toggle="yes">P</italic>-value</th>
                  </tr>
                  <tr>
                    <th colspan="1" rowspan="1">Present</th>
                    <th colspan="1" rowspan="1">Absent</th>
                    <th colspan="1" rowspan="1">Total</th>
                  </tr>
                  <tr>
                    <th colspan="1" rowspan="1">(N=29)</th>
                    <th colspan="1" rowspan="1">(N=105)</th>
                    <th colspan="1" rowspan="1">(N=134)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="1" rowspan="1">Age</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.15<xref rid="tbl1fna" ref-type="table-fn">a</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Mean (SD)</td>
                    <td align="char" colspan="1" rowspan="1">55.0 (15.02)</td>
                    <td align="char" colspan="1" rowspan="1">59.9 (12.31)</td>
                    <td align="char" colspan="1" rowspan="1">58.8 (13.04)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Gender, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.07<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Female</td>
                    <td align="char" colspan="1" rowspan="1">15 (51.7%)</td>
                    <td align="char" colspan="1" rowspan="1">35 (33.3%)</td>
                    <td align="char" colspan="1" rowspan="1">50 (37.3%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Male</td>
                    <td align="char" colspan="1" rowspan="1">14 (48.3%)</td>
                    <td align="char" colspan="1" rowspan="1">70 (66.7%)</td>
                    <td align="char" colspan="1" rowspan="1">84 (62.7%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Race, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.65<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> White</td>
                    <td align="char" colspan="1" rowspan="1">29 (100.0%)</td>
                    <td align="char" colspan="1" rowspan="1">102 (97.1%)</td>
                    <td align="char" colspan="1" rowspan="1">131 (97.8%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Black or African American</td>
                    <td align="char" colspan="1" rowspan="1">0 (0.0%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (1.0%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (0.7%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Not reported: patient refused or not available</td>
                    <td align="char" colspan="1" rowspan="1">0 (0.0%)</td>
                    <td align="char" colspan="1" rowspan="1">2 (1.9%)</td>
                    <td align="char" colspan="1" rowspan="1">2 (1.5%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Primary Site, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Head</td>
                    <td align="char" colspan="1" rowspan="1">2 (6.9%)</td>
                    <td align="char" colspan="1" rowspan="1">10 (9.6%)</td>
                    <td align="char" colspan="1" rowspan="1">12 (9.0%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Neck</td>
                    <td align="char" colspan="1" rowspan="1">2 (6.9%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (1.0%)</td>
                    <td align="char" colspan="1" rowspan="1">3 (2.3%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Upper extremity</td>
                    <td align="char" colspan="1" rowspan="1">4 (13.8%)</td>
                    <td align="char" colspan="1" rowspan="1">10 (9.6%)</td>
                    <td align="char" colspan="1" rowspan="1">14 (10.5%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Lower extremity</td>
                    <td align="char" colspan="1" rowspan="1">6 (20.7%)</td>
                    <td align="char" colspan="1" rowspan="1">19 (18.3%)</td>
                    <td align="char" colspan="1" rowspan="1">25 (18.8%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Trunk</td>
                    <td align="char" colspan="1" rowspan="1">10 (34.5%)</td>
                    <td align="char" colspan="1" rowspan="1">20 (19.2%)</td>
                    <td align="char" colspan="1" rowspan="1">30 (22.6%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Ocular</td>
                    <td align="char" colspan="1" rowspan="1">1 (3.4%)</td>
                    <td align="char" colspan="1" rowspan="1">24 (23.1%)</td>
                    <td align="char" colspan="1" rowspan="1">25 (18.8%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Lactate dehydrogenase</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.39<xref rid="tbl1fna" ref-type="table-fn">a</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> N</td>
                    <td colspan="1" rowspan="1">26</td>
                    <td colspan="1" rowspan="1">86</td>
                    <td colspan="1" rowspan="1">112</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Mean (SD)</td>
                    <td align="char" colspan="1" rowspan="1">404.3 (525.21)</td>
                    <td align="char" colspan="1" rowspan="1">345.4 (437.34)</td>
                    <td align="char" colspan="1" rowspan="1">359.1 (457.40)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Median</td>
                    <td colspan="1" rowspan="1">251.0</td>
                    <td colspan="1" rowspan="1">210.5</td>
                    <td colspan="1" rowspan="1">213.0</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Range</td>
                    <td colspan="1" rowspan="1">132.0, 2800.0</td>
                    <td colspan="1" rowspan="1">68.0, 3264.0</td>
                    <td colspan="1" rowspan="1">68.0, 3264.0</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Previous Radiation Therapy, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Yes</td>
                    <td align="char" colspan="1" rowspan="1">8 (27.6%)</td>
                    <td align="char" colspan="1" rowspan="1">40 (38.1%)</td>
                    <td align="char" colspan="1" rowspan="1">48 (35.8%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">21 (72.4%)</td>
                    <td align="char" colspan="1" rowspan="1">65 (61.9%)</td>
                    <td align="char" colspan="1" rowspan="1">86 (64.2%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Prior Vaccine Therapy, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.33<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Yes</td>
                    <td align="char" colspan="1" rowspan="1">1 (3.4%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (1.0%)</td>
                    <td align="char" colspan="1" rowspan="1">2 (1.5%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">28 (96.6%)</td>
                    <td align="char" colspan="1" rowspan="1">104 (99.0%)</td>
                    <td align="char" colspan="1" rowspan="1">132 (98.5%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Prior Limb Profusion, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.36<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Yes</td>
                    <td align="char" colspan="1" rowspan="1">0 (0.0%)</td>
                    <td align="char" colspan="1" rowspan="1">3 (2.9%)</td>
                    <td align="char" colspan="1" rowspan="1">3 (2.2%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">29 (100.0%)</td>
                    <td align="char" colspan="1" rowspan="1">102 (97.1%)</td>
                    <td align="char" colspan="1" rowspan="1">131 (97.8%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Prior Hormonal Therapy, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.06<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">28 (96.6%)</td>
                    <td align="char" colspan="1" rowspan="1">105 (100.0%)</td>
                    <td align="char" colspan="1" rowspan="1">133 (99.3%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Unknown</td>
                    <td align="char" colspan="1" rowspan="1">1 (3.4%)</td>
                    <td align="char" colspan="1" rowspan="1">0 (0.0%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (0.7%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Prior Chemotherapy, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.24<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Yes</td>
                    <td align="char" colspan="1" rowspan="1">3 (10.3%)</td>
                    <td align="char" colspan="1" rowspan="1">25 (23.8%)</td>
                    <td align="char" colspan="1" rowspan="1">28 (20.9%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">26 (89.7%)</td>
                    <td align="char" colspan="1" rowspan="1">79 (75.2%)</td>
                    <td align="char" colspan="1" rowspan="1">105 (78.4%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Unknown</td>
                    <td align="char" colspan="1" rowspan="1">0 (0.0%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (1.0%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (0.7%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                </tbody>
              </table>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th rowspan="3" colspan="1" />
                    <th colspan="3" rowspan="1">cfDNA BRAF<hr />
                    </th>
                    <th rowspan="3" colspan="1">
                      <italic toggle="yes">P</italic>-value</th>
                  </tr>
                  <tr>
                    <th colspan="1" rowspan="1">Present</th>
                    <th colspan="1" rowspan="1">Absent</th>
                    <th colspan="1" rowspan="1">Total</th>
                  </tr>
                  <tr>
                    <th colspan="1" rowspan="1">(N=29)</th>
                    <th colspan="1" rowspan="1">(N=105)</th>
                    <th colspan="1" rowspan="1">(N=134)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="1" rowspan="1">Prior Immunotherapy, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.65<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Yes</td>
                    <td align="char" colspan="1" rowspan="1">10 (34.5%)</td>
                    <td align="char" colspan="1" rowspan="1">41 (39.0%)</td>
                    <td align="char" colspan="1" rowspan="1">51 (38.1%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">19 (65.5%)</td>
                    <td align="char" colspan="1" rowspan="1">64 (61.0%)</td>
                    <td align="char" colspan="1" rowspan="1">83 (61.9%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Prior Anti-angiogenesis Therapy, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">28 (96.6%)</td>
                    <td align="char" colspan="1" rowspan="1">105 (100.0%)</td>
                    <td align="char" colspan="1" rowspan="1">133 (99.3%)</td>
                    <td align="char" colspan="1" rowspan="1">.06<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Unknown</td>
                    <td align="char" colspan="1" rowspan="1">1 (3.4%)</td>
                    <td align="char" colspan="1" rowspan="1">0 (0.0%)</td>
                    <td align="char" colspan="1" rowspan="1">1 (0.7%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Prior Ipilimumab, n (%)</td>
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td colspan="1" rowspan="1" />
                    <td align="char" colspan="1" rowspan="1">.92<xref rid="tbl1fnb" ref-type="table-fn">b</xref>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> Yes</td>
                    <td align="char" colspan="1" rowspan="1">5 (17.2%)</td>
                    <td align="char" colspan="1" rowspan="1">19 (18.1%)</td>
                    <td align="char" colspan="1" rowspan="1">24 (17.9%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1"> No</td>
                    <td align="char" colspan="1" rowspan="1">24 (82.8%)</td>
                    <td align="char" colspan="1" rowspan="1">86 (81.9%)</td>
                    <td align="char" colspan="1" rowspan="1">110 (82.1%)</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="tbl1fna">
                  <label>a</label>
                  <p id="ntpara0020">Kruskal-Wallis <italic toggle="yes">P</italic>-value.</p>
                </fn>
              </table-wrap-foot>
              <table-wrap-foot>
                <fn id="tbl1fnb">
                  <label>b</label>
                  <p id="ntpara0025">Chi-Square <italic toggle="yes">P</italic>-value.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </p>
        </sec>
        <sec id="sec2.2">
          <title>Association of cfDNA Results With PFS and OS</title>
          <p id="p0085">Among patients with mutant <italic toggle="yes">BRAF</italic> V600 by tissue testing, patients with detectable cfDNA <italic toggle="yes">BRAF</italic> V600E/K mutations had a poorer prognosis than patients with no cfDNA detected (median PFS, 5.8 vs 12.0 months; <italic toggle="yes">P</italic> =.051; OS, 9.2 vs 27.1 months; <italic toggle="yes">P</italic> =.054; <xref rid="tbl2" ref-type="table">Table 2</xref>; <xref rid="fig2" ref-type="fig">Figure 2</xref>).<table-wrap position="float" id="tbl2" orientation="portrait">
              <label>Table 2</label>
              <caption>
                <p>Progression-Free Survival and Overall Survival</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th colspan="1" rowspan="1">
                      <italic toggle="yes">BRAF</italic> Mutation</th>
                    <th colspan="1" rowspan="1">Blood<sup>+</sup>/Tissue<sup>+</sup>
                    </th>
                    <th colspan="1" rowspan="1">Blood<sup>−</sup>/Tissue<sup>+</sup>
                    </th>
                    <th colspan="1" rowspan="1">
                      <italic toggle="yes">P</italic>
                    </th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="1" rowspan="1">No. of patients</td>
                    <td align="char" colspan="1" rowspan="1">11</td>
                    <td align="char" colspan="1" rowspan="1">9</td>
                    <td colspan="1" rowspan="1" />
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Median progression-free survival (mo)</td>
                    <td align="char" colspan="1" rowspan="1">5.8</td>
                    <td align="char" colspan="1" rowspan="1">12.0</td>
                    <td align="char" colspan="1" rowspan="1">.051</td>
                  </tr>
                  <tr>
                    <td colspan="1" rowspan="1">Median overall survival (mo)</td>
                    <td align="char" colspan="1" rowspan="1">9.2</td>
                    <td align="char" colspan="1" rowspan="1">27.1</td>
                    <td align="char" colspan="1" rowspan="1">.054</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
            <fig id="fig2" position="float" orientation="portrait">
              <label>Figure 2</label>
              <caption>
                <p>Overall survival (OS) and progression-free survival (PFS) in patients with and without detectable cell-free DNA <italic toggle="yes">BRAF</italic> V600E/K. NE, not evaluable.</p>
              </caption>
              <graphic position="float" orientation="portrait" ns0:href="gr2.jpg" />
            </fig>
          </p>
          <p id="p0090">Patients without detectable <italic toggle="yes">BRAF</italic> mutations in tissue or blood had PFS and OS superior to mutations with tumor-tissue <italic toggle="yes">BRAF</italic> mutations and positive cfDNA <italic toggle="yes">BRAF</italic> V600E/K detected in plasma. However, patients with <italic toggle="yes">BRAF</italic>-mutated tumor tissue without cfDNA <italic toggle="yes">BRAF</italic> V600E/K detection have improved PFS and OS (undetected cfDNA <italic toggle="yes">BRAF</italic>: median PFS, 5.5 months; OS, 11.1 months).</p>
        </sec>
        <sec id="sec2.3">
          <title>Multivariate Analysis</title>
          <p id="p0095">For PFS, elevated LDH levels at baseline had 2.5 times the risk for an event (HR, 2.47; 95% CI, 1.72 to 3.56; <italic toggle="yes">P</italic>&lt;.0001) compared with normal LDH levels. For OS, elevated LDH levels had 2.5 times increased risk for death (HR, 2.13; 95% CI, 1.45 to 3.14; <italic toggle="yes">P</italic>&lt;.0001) compared with normal LDH levels. Male sex had 60% increased risk for death compared with female sex (HR, 1.58; 95% CI, 1.05 to 2.36; <italic toggle="yes">P</italic>=.027). A limitation to the multivariate analysis is that it is underpowered.</p>
        </sec>
      </sec>
      <sec id="sec3">
        <title>Discussion</title>
        <p id="p0100">Our study demonstrated that the absence of detectable cfDNA <italic toggle="yes">BRAF</italic> V600E/K mutations is associated with improved PFS and OS in patients with <italic toggle="yes">BRAF</italic>-mutant advanced melanoma in a clinical trial patient population without <italic toggle="yes">BRAF</italic>-targeted therapy. The results are of borderline statistical significance but correlate with findings from other studies.<xref rid="bib2" ref-type="bibr">
            <sup>2</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib6" ref-type="bibr">
            <sup>6</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib17" ref-type="bibr">
            <sup>17</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib18" ref-type="bibr">
            <sup>18</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib22" ref-type="bibr">
            <sup>22</sup>
          </xref> Further validation with a larger sample size is warranted. In addition, this trial was completed before targeted therapy and immunotherapy treatment availability and therefore these results may differ in patients with contemporary management.</p>
        <p id="p0105">The cfDNA assay used in this study has high specificity and lower sensitivity for detecting cfDNA <italic toggle="yes">BRAF</italic> V600E/K when using tissue testing to define a “true” positive or negative result. This is not unexpected because the concentration of tumor-specific DNA in the peripheral circulation may be low and below the limits of detection, particularly in patients with indolent and/or low burden disease. The cfDNA testing for <italic toggle="yes">BRAF</italic> V600 mutations alone may therefore be more promising as indicators of prognosis and response to therapy than as a screening tool for early diagnosis.</p>
        <p id="p0110">We summarize the findings of past research that assessed cfDNA <italic toggle="yes">BRAF</italic> in melanoma based on prognosis and sensitivity/specificity in <xref rid="tbl3" ref-type="table">Table 3</xref>.<xref rid="bib2" ref-type="bibr">
            <sup>2</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib5" ref-type="bibr">
            <sup>5</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib16" ref-type="bibr">
            <sup>16</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib18" ref-type="bibr">
            <sup>18</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib19" ref-type="bibr">
            <sup>19</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib33" ref-type="bibr">32</xref> The number of patients varied from 26 to 221 in a variety of research settings, which included cohorts, single-arm trials, and clinical trials. There is a significant amount of heterogeneity among the studies, with various stages of melanoma; however, the studies most commonly included stage III to IV. Studies used serum, plasma, or both for cfDNA testing. There were a variety of interventions used to treat patients, which may affect the reported PFS and OS. Overall, patients with negative or quantitatively lower levels of circulating cfDNA <italic toggle="yes">BRAF</italic> had improved PFS and OS.<table-wrap position="float" id="tbl3" orientation="portrait">
            <label>Table 3</label>
            <caption>
              <p>Comparison of Cell-Free DNA <italic toggle="yes">BRAF</italic> Diagnostic and Prognostic Studies in Melanoma</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th colspan="1" rowspan="1">Reference, year</th>
                  <th colspan="1" rowspan="1">Type of Study</th>
                  <th colspan="1" rowspan="1">Technique</th>
                  <th colspan="1" rowspan="1">Stage</th>
                  <th colspan="1" rowspan="1">Sample</th>
                  <th colspan="1" rowspan="1">Intervention</th>
                  <th colspan="1" rowspan="1">N</th>
                  <th colspan="1" rowspan="1">Sensitivity</th>
                  <th colspan="1" rowspan="1">Specificity</th>
                  <th colspan="1" rowspan="1">PFS (blood<sup>+</sup> vs blood<sup>−</sup>)</th>
                  <th colspan="1" rowspan="1">OS (blood<sup>+</sup> vs blood<sup>−</sup>)</th>
                  <th colspan="1" rowspan="1">Other</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td colspan="1" rowspan="1">Slostad et al, current study, 2018</td>
                  <td align="center" colspan="1" rowspan="1">Phase 2 clinical trial</td>
                  <td align="center" colspan="1" rowspan="1">Digital droplet PCR</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">Carboplatin, paclitaxel, bevacizumab ± everolimus</td>
                  <td align="center" colspan="1" rowspan="1">63</td>
                  <td align="center" colspan="1" rowspan="1">55%</td>
                  <td align="center" colspan="1" rowspan="1">97.70%</td>
                  <td align="center" colspan="1" rowspan="1">5.8 vs 12.0 mo (<italic toggle="yes">P</italic>=.051)</td>
                  <td align="center" colspan="1" rowspan="1">9.2 vs 27.1 mo (<italic toggle="yes">P</italic>=.054)</td>
                  <td align="center" colspan="1" rowspan="1">PPV 91.7%; NPV 82.4%</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Long-Mira et al,<xref rid="bib23" ref-type="bibr">
                      <sup>23</sup>
                    </xref> 2018</td>
                  <td align="center" colspan="1" rowspan="1">Cohort</td>
                  <td align="center" colspan="1" rowspan="1">Idylla PCR</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">10</td>
                  <td align="center" colspan="1" rowspan="1">79%</td>
                  <td align="center" colspan="1" rowspan="1">100%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">Nonsignificant (<italic toggle="yes">P</italic>=.23)</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Gonzalez-Cao et al,<xref rid="bib24" ref-type="bibr">
                      <sup>24</sup>
                    </xref> 2017</td>
                  <td align="center" colspan="1" rowspan="1">Clinical trial</td>
                  <td align="center" colspan="1" rowspan="1">Peptide-nucleic acid probe and reverse transcriptase PCR</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Serum/plasma</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">54</td>
                  <td align="center" colspan="1" rowspan="1">78% (combined E/K)</td>
                  <td align="center" colspan="1" rowspan="1">100%</td>
                  <td align="center" colspan="1" rowspan="1">3.5 vs 15.1 mo (<italic toggle="yes">P</italic>&lt;.0001)</td>
                  <td align="center" colspan="1" rowspan="1">5.3 vs not reached (<italic toggle="yes">P</italic>&lt;.0001)</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Momtaz et al,<xref rid="bib25" ref-type="bibr">
                      <sup>25</sup>
                    </xref> 2017</td>
                  <td align="center" colspan="1" rowspan="1">Single-arm adjuvant phase 2 trial</td>
                  <td align="center" colspan="1" rowspan="1">Digital droplet PCR</td>
                  <td align="center" colspan="1" rowspan="1">IIIC</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">BRAF inhibitor</td>
                  <td align="center" colspan="1" rowspan="1">21</td>
                  <td align="center" colspan="1" rowspan="1">53%</td>
                  <td align="center" colspan="1" rowspan="1">100%</td>
                  <td align="center" colspan="1" rowspan="1">Relapse-free survival 28.6%</td>
                  <td align="center" colspan="1" rowspan="1">OS 78% (at 2 y)</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Janku et al,<xref rid="bib5" ref-type="bibr">
                      <sup>5</sup>
                    </xref> 2016</td>
                  <td align="center" colspan="1" rowspan="1">Cohort</td>
                  <td align="center" colspan="1" rowspan="1">PCR</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">BRAF/MEK inhibitors</td>
                  <td align="center" colspan="1" rowspan="1">36</td>
                  <td align="center" colspan="1" rowspan="1">73%</td>
                  <td align="center" colspan="1" rowspan="1">98%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">Cell-free <italic toggle="yes">BRAF</italic> &gt;2% 4.4 mo vs ≤2% 11.5 mo</td>
                  <td align="center" colspan="1" rowspan="1">PPV 96%; NPV 85%</td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Schreuer et al,<xref rid="bib26" ref-type="bibr">
                      <sup>26</sup>
                    </xref> 2016</td>
                  <td align="center" colspan="1" rowspan="1">Single-arm translational study</td>
                  <td align="center" colspan="1" rowspan="1">Allele-specific quantitative PCR</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">BRAF/MEK inhibitors</td>
                  <td align="center" colspan="1" rowspan="1">36</td>
                  <td align="center" colspan="1" rowspan="1">70%</td>
                  <td align="center" colspan="1" rowspan="1">100%</td>
                  <td align="center" colspan="1" rowspan="1">63% progressive disease 1 mo; 100% in 2 mo (<italic toggle="yes">P</italic>&lt;.01); vs 86% 1 mo, 76% 2 mo</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Gray et al,<xref rid="bib27" ref-type="bibr">
                      <sup>27</sup>
                    </xref> 2015</td>
                  <td align="center" colspan="1" rowspan="1">Single-arm translational study</td>
                  <td align="center" colspan="1" rowspan="1">Quantitiati-ve PCR digital droplet</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">MAPK inhibitors, immunotherapy</td>
                  <td align="center" colspan="1" rowspan="1">48</td>
                  <td align="center" colspan="1" rowspan="1">65%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">10 copies &gt;6 mo; &gt;10 copies &lt;6 mo (<italic toggle="yes">P</italic>&lt;.05)</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Gonzalez-Cao,<xref rid="bib28" ref-type="bibr">
                      <sup>28</sup>
                    </xref> 2015</td>
                  <td align="center" colspan="1" rowspan="1">Cohort</td>
                  <td align="center" colspan="1" rowspan="1">BRAF inhibitor</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Serum/plasma</td>
                  <td align="center" colspan="1" rowspan="1">BRAF inhibitor</td>
                  <td align="center" colspan="1" rowspan="1">22</td>
                  <td align="center" colspan="1" rowspan="1">58%</td>
                  <td align="center" colspan="1" rowspan="1">100%</td>
                  <td align="center" colspan="1" rowspan="1">3.6 vs 13.4 mo (<italic toggle="yes">P</italic>=.021)</td>
                  <td align="center" colspan="1" rowspan="1">7 vs 21.8 mo, (<italic toggle="yes">P</italic>=.017)</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Sanmamed et al,<xref rid="bib2" ref-type="bibr">
                      <sup>2</sup>
                    </xref> 2015</td>
                  <td align="center" colspan="1" rowspan="1">Randomized controlled trial</td>
                  <td align="center" colspan="1" rowspan="1">Quantitative PCR digital droplet</td>
                  <td align="center" colspan="1" rowspan="1">Unresectable IIIC-IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">BRAF inhibitors</td>
                  <td align="center" colspan="1" rowspan="1">28</td>
                  <td align="center" colspan="1" rowspan="1">84%</td>
                  <td align="center" colspan="1" rowspan="1">NA</td>
                  <td align="center" colspan="1" rowspan="1">Higher vs lower no. of copies: 3 vs 9 mo (<italic toggle="yes">P</italic>=.024)</td>
                  <td align="center" colspan="1" rowspan="1">8.6 vs 27.7 mo (<italic toggle="yes">P</italic>=.001)</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Panka et al,<xref rid="bib29" ref-type="bibr">
                      <sup>29</sup>
                    </xref> 2014</td>
                  <td align="center" colspan="1" rowspan="1">Cohort</td>
                  <td align="center" colspan="1" rowspan="1">Reverse transcriptase PCR</td>
                  <td align="center" colspan="1" rowspan="1">II-IV</td>
                  <td align="center" colspan="1" rowspan="1">Blood-based</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">128</td>
                  <td align="center" colspan="1" rowspan="1">96%</td>
                  <td align="center" colspan="1" rowspan="1">0.95</td>
                  <td align="center" colspan="1" rowspan="1">5-y relapse-free survival: 52% vs 57% (<italic toggle="yes">P</italic>=.98)</td>
                  <td align="center" colspan="1" rowspan="1">5-y OS: 73% vs 75% (<italic toggle="yes">P</italic>=.88)</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Aung et al,<xref rid="bib30" ref-type="bibr">
                      <sup>30</sup>
                    </xref> 2014</td>
                  <td align="center" colspan="1" rowspan="1">Blinded cohort</td>
                  <td align="center" colspan="1" rowspan="1">ARMS PCR</td>
                  <td align="center" colspan="1" rowspan="1">Advanced</td>
                  <td align="center" colspan="1" rowspan="1">Serum/plasma</td>
                  <td align="center" colspan="1" rowspan="1">MEK1/2 inhibitors</td>
                  <td align="center" colspan="1" rowspan="1">221</td>
                  <td align="center" colspan="1" rowspan="1">44%-52%</td>
                  <td align="center" colspan="1" rowspan="1">96%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Ascierto et al,<xref rid="bib31" ref-type="bibr">
                      <sup>31</sup>
                    </xref> 2013</td>
                  <td align="center" colspan="1" rowspan="1">Phase 2 clinical trial</td>
                  <td align="center" colspan="1" rowspan="1">BEAMing Technology (Inostics, Baltimore, MD)</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">BRAF inhibitor</td>
                  <td align="center" colspan="1" rowspan="1">72</td>
                  <td align="center" colspan="1" rowspan="1">79%</td>
                  <td align="center" colspan="1" rowspan="1">100%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Board et al,<xref rid="bib19" ref-type="bibr">
                      <sup>19</sup>
                    </xref> 2009</td>
                  <td align="center" colspan="1" rowspan="1">Phase 2 clinical trial</td>
                  <td align="center" colspan="1" rowspan="1">ARMS PCR</td>
                  <td align="center" colspan="1" rowspan="1">III-IV</td>
                  <td align="center" colspan="1" rowspan="1">Serum</td>
                  <td align="center" colspan="1" rowspan="1">MEK1/2 inhibitor</td>
                  <td align="center" colspan="1" rowspan="1">126</td>
                  <td align="center" colspan="1" rowspan="1">56%</td>
                  <td align="center" colspan="1" rowspan="1">94%</td>
                  <td align="center" colspan="1" rowspan="1">No difference (data not shown)</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Shinozaki et al,<xref rid="bib18" ref-type="bibr">
                      <sup>18</sup>
                    </xref> 2007</td>
                  <td align="center" colspan="1" rowspan="1">Cohort</td>
                  <td align="center" colspan="1" rowspan="1">Quantitative Reverse transcriptase PCR + PNA clamp, FRET LNA probe</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Serum</td>
                  <td align="center" colspan="1" rowspan="1">Dacarbazine, cisplatin, vinblastine, and tamoxifen; interleukin 2 and interferon α-2b</td>
                  <td align="center" colspan="1" rowspan="1">103</td>
                  <td align="center" colspan="1" rowspan="1">39%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">NA</td>
                  <td align="center" colspan="1" rowspan="1">13 vs 30.6 mo</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Yancovitz,<xref rid="bib33" ref-type="bibr">
                      <sup>32</sup>
                    </xref> 2007</td>
                  <td align="center" colspan="1" rowspan="1">Cohort</td>
                  <td align="center" colspan="1" rowspan="1">MS-PCR</td>
                  <td align="center" colspan="1" rowspan="1">IV</td>
                  <td align="center" colspan="1" rowspan="1">Plasma</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">26</td>
                  <td align="center" colspan="1" rowspan="1">54%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td colspan="1" rowspan="1" />
                </tr>
                <tr>
                  <td colspan="1" rowspan="1">Daniotti et al,<xref rid="bib22" ref-type="bibr">
                      <sup>22</sup>
                    </xref> 2007</td>
                  <td align="center" colspan="1" rowspan="1">Randomized controlled trial</td>
                  <td align="center" colspan="1" rowspan="1">Allele-specific PCR</td>
                  <td align="center" colspan="1" rowspan="1">I-IV</td>
                  <td align="center" colspan="1" rowspan="1">Serum/plasma</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">45</td>
                  <td align="center" colspan="1" rowspan="1">38%</td>
                  <td align="center" colspan="1" rowspan="1">71%</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td align="center" colspan="1" rowspan="1">—</td>
                  <td colspan="1" rowspan="1" />
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>ARMS, amplification refractory mutation testing system; FRET LNA, fluorescence resonance energy transfer, locked nucleic acid; MAPK, mitogen-activated protein kinase; MS-PCR, mutant-specific polymerase chain reaction; NA, not available; NPV, negative predictive value; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival; PNA, ; PPV, positive predictive value.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p id="p0115">The cfDNA assay does not test for copy number variants and therefore it could miss mutations with loss of heterozygosity, deletions, gains, and amplifications.<xref rid="bib7" ref-type="bibr">
            <sup>7</sup>
          </xref>
          <sup>,</sup>
          <xref rid="bib14" ref-type="bibr">
            <sup>14</sup>
          </xref> However, a cfDNA assay still may assess for heterogeneity better than a tissue sample because tissue heterogeneity can exist even between metastatic sites. In 1 melanoma study, there were <italic toggle="yes">BRAF</italic> V600 mutation inconsistencies of up to 14.5% between foci of primary tumor and metastatic site.<xref rid="bib32" ref-type="bibr">
            <sup>33</sup>
          </xref> In addition, the differences in prognosis in patients with baseline presence or absence of cfDNA <italic toggle="yes">BRAF</italic> mutation before therapy may be a useful stratification tool for future clinical trials.</p>
        <p id="p0120">We detected cfDNA <italic toggle="yes">BRAF</italic> V600E/K in a patient with a <italic toggle="yes">BRAF</italic> V600 wild-type tumor. One patient in our study was cfDNA <italic toggle="yes">BRAF</italic> positive in the plasma with negative <italic toggle="yes">BRAF</italic> mutation testing in cutaneous tissue. She was a 29-year-old woman with a primary truncal melanoma and she underwent wide local excision of the primary tumor with sentinel lymph node dissection. It is unknown whether her tissue sample was from the primary or metastatic site. She received prior immunotherapy (Interferon alpha as adjuvant therapy) but she did not receive chemotherapy, ipilimumab, radiation, vaccine therapy, or anti-angiogenesis therapy. She was treated with the chemotherapy protocol with carboplatin, paclitaxel, bevacizumab, and everolimus. Her disease progressed after 1.9 months and she died 18.4 months posttreatment from cancer-related causes.</p>
        <p id="p0125">The patient’s PFS was worse than the median PFS (5.8 months) of patients with cfDNA <italic toggle="yes">BRAF</italic> positivity in plasma and <italic toggle="yes">BRAF</italic> mutation in tissue. This suggests that cfDNA blood sampling may detect mutations in patients with false-negative tissue testing results, with the false-negative in the tissue potentially explained by inadequate tissue, a second melanoma primary site, or the possibility of tissue heterogeneity.<xref rid="bib7" ref-type="bibr">
            <sup>7</sup>
          </xref> Our patient may have had an unknown secondary primary melanoma that could have been targeted by BRAF inhibitor therapy. Clinician awareness of cfDNA <italic toggle="yes">BRAF</italic> detection by ddPCR may have led to different therapeutic options that possibly could have affected the patient’s prognosis.</p>
      </sec>
      <sec id="sec4">
        <title>Conclusion</title>
        <p id="p0130">The absence of detectable cfDNA <italic toggle="yes">BRAF</italic> V600 E/K in the peripheral circulation is a positive prognostic marker for patients with metastatic melanoma. The NCCTG N0879 participants with <italic toggle="yes">BRAF</italic> V600 mutant tumors and detectable cfDNA <italic toggle="yes">BRAF</italic> V600E/K experienced shorter PFS and OS. This provides support for the evolving concept that cfDNA reflects overall tumor burden and prognosis. The cfDNA testing provides a minimally invasive test that has the opportunity for serial monitoring with promising prognostic implications for patient care. Our study also suggests that cfDNA <italic toggle="yes">BRAF</italic> testing would be an important test for patient stratification in future melanoma clinical trials. Further investigations with a larger sample size in patients with <italic toggle="yes">BRAF</italic> targeted therapy are needed to further investigate the prognostic, predictive, and diagnostic value of cfDNA <italic toggle="yes">BRAF</italic> V600E/K detection in melanoma.</p>
      </sec>
    </body>
  </article>
</pmc-articleset>